The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,650.00
Ask: 1,749.00
Change: 0.00 (0.00%)
Spread: 99.00 (6.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Global Stocks Hit By Yuan Devaluation

Wed, 12th Aug 2015 16:11

LONDON (Alliance News) - Stocks across Europe ended lower Wednesday, while Wall Street remained in negative territory at the London close, after Chinese authorities devalued the yuan for the second time in as many days, with the pound regaining ground lost after a disappointing UK jobs report.

The FTSE 100 index ended down 1.4% at 6,571.19 points, and the FTSE 250 finished down 1.3% at 17,438.09, meaning it is the second consecutive negative close for both indices. The AIM-All Share shed 0.8% at 748.62.

However, London held up better than other European stock markets. The CAC 40 in Paris ended down 3.4%, and the DAX 30 in Frankfurt fell 3.3%.

At the European equities markets close, US stocks also were trading lower, with the Dow 30 down 1.3% and the S&P 500 and Nasdaq Composite both down 1.1%.

The sell-off of global stocks came after China's central bank cut its reference rate for a second time Wednesday following its surprise reduction on Tuesday. The People's Bank of China on Wednesday adjusted its daily reference exchange rate by a further 1.6%, setting it at 6.3306 to the US dollar. The central bank had devalued the yuan by 1.9% on Tuesday. The dollar traded the yuan at CNY6.3836 late Wednesday, having hit a four-year high at CNY6.4374 earlier in the day.

Addressing market concerns Wednesday, China's central bank said there was no basis for a sustained depreciation of the yuan given international and domestic economic conditions. The PBoC had said on Tuesday that the devaluation was a one-time adjustment.

The International Monetary Fund said Beijing's move to devalue the yuan was "a welcome step", to allow market forces to have a greater role in determining the exchange rate. Similarly, the European Commission also said the move was a "positive development".

But some analysts were concerned that the Chinese devaluation to support its exports could spark a currency war, with countries trying to hold onto their share of global exports.

"In isolation, currency devaluation improves global competitiveness, but if what follows are further rounds of devaluations from competing economies, then a currency war may begin; and this is rarely a force for good in the global economy," said Brewin Dolphin Head of Fund Research Ben Gutteridge.

Nevertheless, Standard & Poor's Ratings Services welcomed the Chinese move, saying it will not trigger a currency war.

"The argument that China is trying to spur growth by weakening its currency to spur exports does not strike us as very convincing," said Standard & Poor's chief economist for Asia-Pacific, Paul Gruenwald. "Exports are more a function of foreign demand, with the exchange rate playing a secondary role. There is no reason for that relationship to have changed."

Societe Generale analyst Aneta Markowska said the move by Chinese authorities means that a September interest rate hike by the US Federal Reserve is now a closer call. The analyst noted that China's decision to devalue the yuan will not only add deflationary pressures but could also have a negligible impact on the US growth.

"The move has the potential of delaying the Fed if it triggers capital outflows out of China and other emerging countries. The Fed wants to engineer a smooth lift-off and will be very sensitive to financial conditions at the time of the September meeting. We stick with our call for a September lift-off, but acknowledge that that it has become a closer call," Markowska said.

The yuan devaluation put the spotlight on quarterly results from US-listed Chinese e-commerce giant Alibaba Group. The company on Wednesday reported a sharp increase in its first-quarter profit, helped by a disposal gain. Revenue increased to 20.245 billion yuan, or USD3.265 billion, from 15.771 billion yuan in the previous year. Wall Street expected revenue of USD3.39 billion for the quarter, however. The company also announced a share buyback. The stock is down 30% since its initial public offering in September last year.

In London, the devaluation again hit mining stocks, as China is the largest consumer of metals, and other exporters to China. Glencore led the FTSE 100 fallers, down 5.7%, hitting a new all-time low during trade, while Anglo American fell 1.9%. Meanwhile, shares of Burberry Group, a luxury goods retailer with significant sales in China, lost 3.5%.

Investors shifted to gold, the traditional safe-haven asset, amid concerns about China, sending the price of the precious metal higher. Gold traded at USD1,124.18 an ounce late Wednesday. As a result, gold miners benefited, with Randgold Resources up 5.4% and Fresnillo up 0.1%.

FTSE 250 gold miner Centamin rose 11%, helped by the rise in gold prices but also by a set of positive results in which it reported a rise in its pretax profit in the first half of 2015, leading the company to increase its interim dividend by 11%. It said pretax profit for the first half of 2015 was USD47.4 million, up from USD31.9 million a year earlier, as revenue climbed to USD259.7 million from USD205.3 million. Centamin raised its interim dividend to 0.97 cents per share from 0.87 cents a year earlier.

Elsewhere, Unilever shares lost 4.3% after Goldman Sachs downgraded it to Sell from Neutral, while International Consolidated Airlines Group fell 4.4% after Kepler Cheuvreux cut the British Airways owner to Hold from Buy.

Zoopla Property Group added 3.9%. The property portal, which competes with Rightmove and which has recently faced the launch of a new player in the form of agency-back OnTheMarket, said it added 213 net new branches to its UK agency membership in the period from April 1 to July 31, returning to growth after having taken a hit from the launch of OnTheMarket. Zoopla added that the uSwitch price comparison business has continued to trade well since being acquired, with a particular boost from the energy switching market and a supportive regulatory environment for the energy business.

Meanwhile, the pound recovered after being hit following a somewhat weak UK jobs report. The UK unemployment rate was 5.6% for the three months to June, compared to 5.5% in three months to March, though down notably from 6.3% in the same period of last year. There were 1.85 million unemployed people in April to June, 25,000 more than in January to March period, data from the Office for National Statistics showed.

Average earnings including bonuses increased 2.4% from last year, missing expectations of a 2.8% rise following a 3.2% rise in the three months to May. Excluding bonus, pay climbed 2.8%, in line with estimates.

More positively, UK jobless claims declined unexpectedly in July. The number of people claiming unemployment benefits declined by 4,900 in July from June, while it was expected to rise by 1,000. The claimant count rate held steady at 2.3% as expected by economists.

The pound fell sharply against the dollar, hitting a low of USD1.5536 after the data. However, sterling recovered and was standing at USD1.5649 when the London stock market closed.

In the economic calendar Thursday, the German and French consumer price indices are due at 0700 BST and 0745 BST, respectively. In the US, retail sales and initial and continuing jobless claims are all expected at 1330 BST. US Business inventories are expected at 1500 BST.

In the UK corporate calendar, Coca-Cola HBC releases half-year results, TUI Group publishes third-quarter results, and Glencore releases its half-year production report. Infinis Energy and Grainger issue interim management statements, while Cineworld Group, Michael Page International, Derwent London and Ophir Energy and Promethean World publish half-year results.

Also Thursday, blue-chips as Fresnillo, Rio Tinto, Diageo, BG Group, BT Group, GlaxoSmithKline and Pearson, among many other London-listed companies, go ex-dividend, meaning new buyers no longer qualify for the latest dividend payout.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.